Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
AAPS J. 2022 May 12;24(3):68. doi: 10.1208/s12248-022-00712-2.
AAPS J. 2022.
PMID: 35554731
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS.
Preithner S, et al. Among authors: elm s.
Mol Immunol. 2006 Mar;43(8):1183-93. doi: 10.1016/j.molimm.2005.07.010. Epub 2005 Aug 15.
Mol Immunol. 2006.
PMID: 16102830
Item in Clipboard
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
Kebenko M, Goebeler ME, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman JB, Friedrich M, Vieser E, Elm S, Patzak I, Wessiepe D, Stienen S, Fiedler W.
Kebenko M, et al. Among authors: elm s.
Oncoimmunology. 2018 Apr 18;7(8):e1450710. doi: 10.1080/2162402X.2018.1450710. eCollection 2018.
Oncoimmunology. 2018.
PMID: 30221040
Free PMC article.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.